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Introduction
Pain has a deleterious impact on an individual's health and wellbeing (1) and common painful conditions, such as chronic musculoskeletal disorders, contribute to a significant number of years lived with disability across the globe (2) . Chronic pain in particular is associated with greatly reduced quality of life, difficulties with activities of daily living (ADL), and often has a negative impact on an individual's emotional and mental health (3) . A substantial body of literature suggests that those with chronic pain have higher rates of depressive and anxiety symptoms than those without chronic pain (4) (5) (6) .
Despite this, the prevalence of chronic pain in persons with severe mental illness (SMI) has received little attention (7, 8) . This is surprising as persons with SMI such schizophrenia and bipolar disorder have a highly increased risk for a plethora of painful physical illnesses including cardiopulmonary diseases, metabolic diseases, bone disorders, viral infections, and cancer (9) (10) (11) (12) . In addition, pain in people with SMI is also associated with a worsening of psychiatric symptoms (7) .
Despite this increased risk of severe co-morbid physical illnesses, most persons with SMI do not receive adequate physical healthcare provision and treatment (13) (14) (15) . Mental health specialists report barriers limiting their ability to treat physical co-morbidity and people with SMI are less likely to recognize or monitor co-occurring medical conditions than the general population (16, 17) .
Additionally many healthcare professionals fail to take people with severe mental illness seriously when they report physical health problems (18). When compared to those without SMI, persons with SMI appear to have an increased likelihood of experiencing conditions that cause pain whilst at the same time having a lower likelihood of receiving adequate care to manage it (9, 10) .
A recent systematic review established that people with schizophrenia, who have been known to have a higher pain threshold for pain than the general population, have a lower prevalence of pain than people with other psychiatric disorders, particularly compared to those with bipolar disorder (19) . However, to date, no systematic review or meta-analysis of pain in individuals with bipolar disorder exists, despite the fact this group appears to be particularly more likely to experience chronic pain and less likely to seek medical help (8) . In fact, people with bipolar disorder reported almost 4 pain complaints at any one time (20) . Moreover, people with bipolar disorder who are treatment adherent report statistically lower levels of pain than their non-treatment adherent counterparts (21) . Clearly, a better understanding of the risk and burden of pain is an important step toward improving clinical outcomes for individuals with bipolar disorder.
Aims of the study
In recognition of the potential for pain to be problematic for people with bipolar disorder, the paper had the following two aims: (1) to establish the prevalence of pain and its moderators in people with bipolar disorder, and (2) to compare the prevalence of pain in bipolar disorder with general population controls.
Method
This systematic review was conducted according to the PRISMA statement (22) following a predetermined, but unpublished protocol.
Inclusion and exclusion criteria
Studies were eligible that fulfilled the following criteria: (1) inclusion of participants with bipolar disorder, diagnosed according to diagnostic criteria (e.g. DSM IV (23) or ICD 10 (24)), a valid screening measure (e.g., Alcohol Use Disorder and Associated Disabilities Interview Schedule-DSM-IV Version) or through medical record review. When we encountered studies containing groups of mixed participants (e.g., with major depressive disorder), we contacted the authors up to two times over a month period to ascertain the variables of interest in bipolar disorder subjects. If these data were not available, we excluded the study. (2) Reporting of the prevalence of pain (of any type) or assessment of pain with a continuous measure with or without comparison to a control group that did not have a mental illness. When a study measured pain with a continuous measure, but did not specify prevalence rates with a cut-off point, we contacted the authors up to two times to obtain this information.
We did not place a language restriction upon our searches. If we came across studies that reported data from the same sample at different time points, we used the most recent data and/ or the largest data set. We excluded studies that (1) reported pain as an adverse event of a drug trial (e.g., for headache), (2) reported the prevalence of bipolar disorder in a sample of patients who all had pain (no other comorbidities were excluded), or (3) in which the pain was experimentally induced. When we encountered studies without a control group that assessed pain in a sample with a continuous measure (e.g., SF 36 bodily pain scale, (25) ), but did not have a cut-off to determine the prevalence of pain, we excluded the study if the authors did not respond to requests for additional data.
Information sources
Two reviewers (BS, DV) independently conducted searches on Academic Search Premier, MEDLINE, EMBASE, Psychology and Behavioral Sciences Collection, PsycINFO, SPORTDiscus, CINAHL Plus and Pubmed. In addition, the reference lists of all eligible articles and recent systematic reviews of the literature were scanned to assess eligibility of additional studies.
Searches
Two independent reviewers (BS, DV) employed the predetermined search strategy using the key words 'bipolar disorder' and 'pain' or 'pain perception' or 'pain management' or 'pain measurement' or 'musculoskeletal pain' or 'pain intensity' or 'chronic pain' or 'neuropathic pain' or 'pain*'.
Study Selection
After the removal of duplicates, two independent reviewers (BS, DV) screened the titles and abstracts of all potentially eligible articles. Both authors applied the eligibility criteria, and a list of full text articles was developed through consensus. Two reviewers (BS, DV) then considered the full texts of these articles and the final list of included articles was reached through consensus.
Data Extraction
Two authors (BS, DV) independently conducted data extraction using a predetermined form. The data collected from each article included: study design, geographical location, bipolar sample and control sample characteristics (number, % male, mean age), bipolar diagnosis method, method of pain assessment (including site, severity, and interference of pain where available) and the prevalence of pain in people with bipolar disorder and controls as defined by the authors.
Methodological quality assessment
Two independent authors (BS, DV) completed methodological quality assessment of included articles using the Newcastle Ottawa Scale (NOS; (26) ). Due to the anticipated paucity of data, we also included studies without a control group. These studies were considered as case control studies for the purposes of methodological assessment in accordance with a previous review (27) . The NOS is utilised to assess the methodological quality of non-randomised trials and has acceptable validity and reliability (26) . The assessment tool focuses on three main methodological features: (1) the selection of the groups, (2) the comparability of the groups and (3) the ascertainment of the outcome of interest. The NOS can be modified and we adapted the NOS to take into account age and gender as comparability measures and considered pain assessment in the exposure category.
Studies are given a score from 0-9, with a score of 5 or greater being indicative of satisfactory methodological quality. We anticipated studies without a control group would score below this and present their results with due consideration.
Meta-analysis
We pooled individual study data using DerSimonian-Laird proportion method (28) . Our predetermined protocol stipulated that heterogeneity would be assessed with the Cochran Q statistic (29) . Since we found significant heterogeneity (Cochran Q = 66988.29 (df = 24) P < 0.0001) a random effects meta-analysis was employed using StatsDirect. We calculated the relative risk (RR) to investigate the differences in pain between those with bipolar disorder and members of the general population when there were three or more studies (Aim 2). When possible, we conducted subgroup analyses to investigate the prevalence of migraine and chronic pain since the literature has suggested these are prevalent in people with bipolar disorder (8) . In order to investigate sources of heterogeneity, we conducted moderator analysis with mean age, percentage of males, NOS score and the method of bipolar disorder classification (comparing DSIM, ICD or any other screening measure). We assessed publication bias with a visual inspection of funnel plots, yet gave priority to quantitative testing through the Begg-Mazumdar Kendall's tau (30) and Egger bias tests (31) .
Results

Study selection
The original search yielded 2,713 potential hits which were reduced to 2,319 after the removal of duplicates. At the eligibility screening stage, a total of 72 articles were deemed potentially eligible and full texts were obtained and reviewed by two authors. In total, 50 articles were excluded with reasons and 22 articles met the eligibility criteria and were included in the review (8, . The full search strategy including reasons for exclusion is presented in figure 1 . 
Methodological quality
The NOS summary score for each article is presented in table 1. All seven studies that had a control group scored high (mean NOS score 7.2±0.48) and were considered good quality. The 15 studies that did not have a control group all scored lower than 5 on the NOS, which was attributable to the absence of a control group; these studies scored zero (out of a possible 5 points) in the areas that compare the bipolar and control groups on selection, comparability, and exposure.
Measurement and location of pain in the bipolar populations
A range of different types of pain were considered. The most commonly investigated pain was headache/migraine (8, 32, 33, 35, 39, 40, 42-44, 47, 52) whilst six studies investigated chronic pain (8, 34, 45, (48) (49) (50) . A wide range of methods were employed to ascertain pain in people with bipolar disorder and are presented in table 1.
Insert table 1 about here Prevalence of pain in persons with bipolar disease
In total, 25 types of pain were investigated and the pooled prevalence of pain was 28.9% (95% CI: 
Insert figure 2a and b about here
Moderators of the prevalence of pain in people with bipolar disorder
Ten studies (32-36, 38, 41, 42, 45, 49) had sufficient data on mean age, percentage of males and bipolar diagnosis method to enable moderator analyses. The moderator analyses demonstrated that mean age (b1 = -0.038, z = -0.311, P = 0.75), % male (b2 = -0.074, z = -1.013, P = 0.311) and method of diagnosing bipolar disorder (b3 = -0.0935, z = -0.092, P = 0.92) did not explain the heterogeneity in the prevalence of pain. We investigated the effect methodological quality (NOS score) on the prevalence of pain across the 22 studies and this suggested that a low NOS score was associated with a high prevalence of pain but this did not reach statistical significance (b1=0.532, z=1.875, p=0.06). Lastly, we investigated the influence of the method of bipolar disorder diagnosis on the prevalence across all studies and this demonstrated that the classification used to diagnose bipolar disorder had no significant effect on the prevalence of pain (b1=0.310, z = 0.524, P = 0.59).
Comparing the prevalence of pain in people with bipolar disorder versus control groups
In each of the 7 studies with a control group, persons with bipolar disease consistently reported a higher prevalence of pain than the comparison group. One study (33) provided pain data for two different types of pain and was corrected for multiple comparisons in the pooled analysis. In total, data from 12,342,577 unique individuals (n with bipolar disorder =138,285 and control n= 12,204,292) indicated that the relative risk of pain in people with bipolar disorder was 2.14 (95% CI = 1.67 -2.75 , Chi-square = 36.623 (df = 1) P < 0.0001; Cochran Q = 1078.49 (df = 7) P < 0.0001). The results from the meta-analysis are presented in figure 3 . The funnel plot of the 7 included studies was not symmetrical indicating possible publication bias. However, the Eggers test (10.931 P = 0.013), but not the Begg Mazumdar: test (Kendall's tau = 0.14; P = 0.7195) showed evidence of publication bias.
Insert figure 3 about here Pooled prevalence of Migraine in people with bipolar disorder
We also calculated the pooled prevalence of migraine in 127,905 individuals across 9 studies (8, 32, 39, 40, 42-44, 47, 52) and this yielded a prevalence of 14.2% (95% CI = 10.6% -18.3%; Cochran Q = 1080.29 (df = 8) P < 0.0001).
Comparing the prevalence of migraine in people with bipolar disorder versus control groups
It was possible to pool the data from 3 comparative studies (8, 44, 52) involving 6,732,220 unique individuals (n with bipolar disorder=126,956, n controls = 6,605,264). The RR was 3.30 (95% CI=2.27-4.80, Chi-square test = 39.408 (df = 1) P < 0.0001).
Pooled prevalence of chronic pain in people with bipolar disorder
It was possible to calculate the pooled prevalence of chronic pain in 106,214 individuals with bipolar disorder across 6 studies (8, 34, 45, (48) (49) (50) . The pooled prevalence of chronic pain was 23.7% (95% CI = 13.1-36.3, Cochran Q= 2200.77 (df = 5) P < 0.0001). Only two comparative studies (8, 49) contained data on chronic pain and it was therefore not possible to meta-analyse these data.
Discussion
To our knowledge this is the first systematic review and meta-analysis investigating the prevalence of pain in people with bipolar disorder. In this large review involving 171,352 persons with bipolar disorder and 12,204,292 controls, we found that a substantial proportion of patients with bipolar disorder reported clinically relevant levels of pain. The overall pooled analysis of pain in people with bipolar disorder was 28.9% and the relative risk was over double for people with bipolar disorder compared to members of the general population. In terms of specific types of pain, the pooled prevalence of chronic pain was high with almost one in four (23.7%) being affected. In addition, migraine affected one in seven (14.2%) persons with bipolar disorder and the comparative analysis demonstrated that people with bipolar disorder are over three times more likely to experience migraines than members of the general population.
Increased levels of pain in persons with bipolar disorder may be explained by several mechanisms. For instance, bipolar disorder and migraine appear to share some specific polymorphisms, with the KIAA0564 gene being particularly implicated, thus suggesting a close association (53, 54) . Also, people with bipolar disorder have an increased prevalence of depression (8, 36) , and depression has been associated with increased physical complaints, and, possibly, greater pain sensitivity (55), opposite to findings in schizophrenia (19) . For example, neuroimaging studies in major depressive disorder indicate that heightened amygdala activity, in part, explains the high comorbidity of pain and depression when these conditions become chronic (56) . However, due to limitations in the available data, we could not investigate the influence of depressive symptoms on the observed results. Other studies have suggested seretonergic and noradrenergic pathway involvement (7, 57) . In addition, specific neuroinflammatory mechanisms responsible for an elevated risk of painful physical comorbidity in people with bipolar disorder may contribute to the higher levels of observed pain (58) . Previous research (59) has found that migraine and bipolar disorder symptoms are closely related and the presence of migraine can influence pain perception.
Since we found that 14.2% of people with bipolar disorder experienced migraine, this could have influenced the variance in the prevalence of pain. Lastly, recent findings (60) also suggest that limited cognitive flexibility and memory capacities may be linked to the mechanisms of pain chronicity and probably also to its neuropathic quality. This may imply that people with bipolar disorder who are known to have deficits in executive functioning or memory have a greater risk of pain chronicity after a painful event. This seems particularly pertinent given the fact that we found across 106,214 individuals with bipolar disorder that almost one in four is affected by chronic pain.
Clinical implications
The results of this review are concerning since pain and in particular chronic pain in people with bipolar disorder is associated with impaired recovery (45) , greater functional incapacitation (44, 61) , lower quality of life (8), and increased risk of suicide compared to people without pain (62) .
Since bipolar disorder is already associated with a greatly increased risk of suicide (63), it is imperative that this population receives adequate pain assessment and management (36) . A central component to this is the training and education of psychiatrists who are in a critical place to oversee the pharmacological management of pain (7). We advocate that systematic assessment of pain should be undertaken as part of the management of bipolar disorders, and that pain should be monitored during the course of treatment. Equally, healthcare professionals dealing with pain should consider mental health complications. Previous work suggests clinicians are more likely to attend to pain than mental distress (64) . The potential benefits of early identification and treatment of pain may not only include a reduction in pain and of its impact on the individual, but may also extend to a reduction of health-care costs and improvement of mental health outcomes.
Of great concern are the high levels of chronic pain experienced by people with bipolar disorder. A better understanding of the association of bipolar disorder and chronic pain could help limit harmful/adverse pharmacological side effects. For instance, in the general population chronic pain is often managed with tri-cyclical antidepressants (65) , yet prescription of such medication to a person with bipolar disorder may inadvertently trigger a manic phase of illness if prescribed in the absence of a mood stabilizer (66) . Commonly used analgesic medications also need careful consideration. For instance, there is sound evidence that non-steroidal anti-inflammatory medications can increase serum lithium levels, impairing renal lithium excretion and possibly eliciting lithium toxicity (67) . Similarly, some stronger analgesic medications such as opioids may have mood altering qualities increasing the risk of eliciting a manic episode (68) .
Limitations of the review
Several limitations, especially of the included literature need to be considered when interpreting the results of our review. First, bipolar disorder is a complex and heterogeneous disorder, and reporting of pain likely varies according to different phases, polarity and acuity of the disease. The paucity of information regarding these illness characteristics made it impossible to systematically evaluate their effects on pain prevalence in patients with bipolar disorder. In addition, the perception and therefore prevalence of pain is known to vary according to the type of bipolar disorder (I or II; (59)) but due to limitations in the data we were not able to disentangle this relationship. In addition, gender may also cause some variance, but our moderator analysis did not elucidate any evidence of a gender effect. Second, all of the included studies utilised a crosssectional measurement of pain and did not correlate pain with mood state or severity of symptoms.
Therefore, prospective longitudinal studies that assess pain prevalence and severity over time and in relationship to mood symptoms and treatments are essential. Third, our results may have been suspect to Berkson's bias, which states that clinical samples are more impaired and experience more pain than non-clinical samples due to self-referral to a clinical setting. Berkson's bias has been observed in the mood dimensions of bipolar disorder (69) and may account for an underreporting within the pooling of epidemiological data. Fourth, none of the included studies used a validated pain assessment scale and subsequently information about the severity, location, variability, and interference of pain during activities is lacking. Fifth, all of the meta-analytic results were heterogeneous and some demonstrated a degree of publication bias. In our moderator analysis, we were not able to explain the heterogeneity with mean age, % males, or the methodological quality of method of classification of bipolar disorder. This finding demonstrates that unknown/unmeasured factors contribute to the observed heterogeneity. Regarding publication bias, the funnel plot for the main analysis (figure 2b) appeared asymmetrical, yet the quantitative investigation of bias did not demonstrate any evidence to support this. This discrepancy may be due to the fact that there is a trend for publication bias, but its magnitude is insufficient to reach statistical significance according to the Eggers test or Begg-Mazumdar test. In addition, the comparative analysis (figure 3) demonstrated some publication bias with the Eggers test, but this finding should be interpreted with caution due to the low number of studies (<10 (70)). Sixth, there was insufficient information about psychotropic and analgesic medication within the bipolar disorder cohorts to enable statistical investigation of these variables on the observed results. Future research should seek to investigate the influence of psychotropic and analgesic medications on pain and particular attention should be paid to the prevalence of pain in people with bipolar disorder who are drug naïve. In the same way, future research should investigate the role of psychiatric co-morbidities including anxiety and substance use disorders on the prevalence of clinical pain in these patients. Finally, we included 15 studies that received low methodological quality ratings. However, the low methodological quality ratings were due to the absence of a control group, and the moderator analysis demonstrated that these studies had no significant effect on the observed results. Despite the aforementioned, higher levels of pain were reported consistently among people with bipolar disorder than in the comparison groups.
Future research
It is essential that future research seeks to clearly assess pain characteristics including noting the site, severity, variability and chronicity. There were insufficient data to analyse these pain characteristics in our meta-analysis. In addition, only one study (8) 
Conclusion
Almost 30% of persons with bipolar disorder experience clinically relevant pain, which was twice as common compared to general population controls. Chronic pain was prevalent affecting almost one in four people, and migraine was over 3 times as common than in the general population. Pain has a range of adverse and deleterious impact upon the individual and may impede recovery, reduce quality of life and have adverse effects on psychiatric symptoms. Therefore, it is essential that treating psychiatrists and the wider multidisciplinary team seek to provide adequate assessment and treatment of pain in people with bipolar disorders. Figure 3 Relative risk of pain in people with bipolar disorder compared to controls (N=7, n=12,342,577)
Pooled relative risk = 2.14 (95% CI = 1.676 -2.75), Chi squared= 36.623 (df = 1) P < 0.0001
Cochran Q = 1078.49 (df = 7) P < 0.0001
Relative risk meta-analysis plot (random effects) 
